Education
About Us
Working with TipRanks
Follow Us
Astrazeneca Plc (AZN)
NASDAQ:AZN
AZN Stock Chart & Stats
$90.61
-$0.10(-0.15%)
At close: 4:00 PM EST
$90.61
-$0.10(-0.15%)
Day’s Range― - ―
52-Week Range$61.24 - $94.02
Previous CloseN/A
Volume1.80M
Average Volume (3M)5.45M
Market Cap
$281.23B
Enterprise Value$264.05B
Total Cash (Recent Filing)$8.18B
Total Debt (Recent Filing)$32.66B
Price to Earnings (P/E)29.6
Beta0.21
Next Earnings
Feb 10, 2026EPS Estimate
1.06Next Dividend Ex-DateN/A
Dividend Yield1.73%
Share Statistics
EPS (TTM)1.19
Shares Outstanding3,101,451,700
10 Day Avg. Volume5,810,380
30 Day Avg. Volume5,445,532
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)4.98
Price to Sales (P/S)3.76
P/FCF Ratio27.92
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue4.54
Enterprise Value/Gross Profit5.52
Enterprise Value/Ebitda14.72
Forecast
1Y Price Target
$102.40Price Target Upside13.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)4.59
Revenue Forecast (FY)$58.53B
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAZN presented full results from the Ph3 BaxHTN trial at the European Society of Cardiology meeting, showing significant reductions in systolic blood pressure for patients with uncontrolled or resistant hypertension.
Product DifferentiationBaxdrostat has a longer half-life than its competitor lorundrostat, allowing for 24-hour coverage and nocturnal blood pressure control.
Regulatory ApprovalPlans are in place to submit the trial data to regulators with a potential US launch, indicating confidence in regulatory approval and market success.
Bears Say
AstraZeneca News
AZN FAQ
What was Astrazeneca Plc’s price range in the past 12 months?
Astrazeneca Plc lowest stock price was $61.24 and its highest was $94.02 in the past 12 months.
What is Astrazeneca Plc’s market cap?
Astrazeneca Plc’s market cap is $281.23B.
When is Astrazeneca Plc’s upcoming earnings report date?
Astrazeneca Plc’s upcoming earnings report date is Feb 10, 2026 which is in 52 days.
How were Astrazeneca Plc’s earnings last quarter?
Astrazeneca Plc released its earnings results on Nov 06, 2025. The company reported $1.19 earnings per share for the quarter, the consensus estimate of $1.19 by $0.
Is Astrazeneca Plc overvalued?
According to Wall Street analysts Astrazeneca Plc’s price is currently Undervalued.
Does Astrazeneca Plc pay dividends?
Astrazeneca Plc pays a Semiannually dividend of $0.515 which represents an annual dividend yield of 1.73%. See more information on Astrazeneca Plc dividends here
What is Astrazeneca Plc’s EPS estimate?
Astrazeneca Plc’s EPS estimate is 1.06.
How many shares outstanding does Astrazeneca Plc have?
Astrazeneca Plc has 3,101,451,700 shares outstanding.
What happened to Astrazeneca Plc’s price movement after its last earnings report?
Astrazeneca Plc reported an EPS of $1.19 in its last earnings report, expectations of $1.19. Following the earnings report the stock price went up 3.229%.
Which hedge fund is a major shareholder of Astrazeneca Plc?
Currently, no hedge funds are holding shares in AZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AstraZeneca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$102.40 (13.01% Upside)
$102.40 (13.01% Upside)
Blogger Sentiment
Bullish
AZN Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.7%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.10%
12-Months-Change
Fundamentals
Return on Equity
21.73%
Trailing 12-Months
Asset Growth
9.09%
Trailing 12-Months
Company Description
Astrazeneca Plc
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN Company Deck
AZN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong growth in revenue and successful pipeline developments, with significant achievements in the oncology segment and positive Phase III trial results. However, challenges persist in China and from Medicare Part D reform, with concerns about the loss of exclusivity for some products.View all AZN earnings summariesAZN Stock 12 Month Forecast
Average Price Target
$102.40
▲(13.01% Upside)
Technical Analysis
Ownership Overview
―
Insiders
5.25% Mutual Funds
5.64% Other Institutional Investors
88.10% Public Companies and Individual Investors